{"DataElement":{"publicId":"6450646","version":"1","preferredName":"Person Malignant Neoplasm Pathology Clinical Trial Eligibility Criteria Malignant Neoplasm Pathology Type","preferredDefinition":"information related to the cellular classification or pathology of a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues, as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial._the type of cellular classification of a malignant neoplasm.","longName":"3178319v1.0:6450618v1.0","context":"NRG","contextVersion":"1","DataElementConcept":{"publicId":"3178319","version":"1","preferredName":"Person Malignant Neoplasm Pathology Clinical Trial Eligibility Criteria","preferredDefinition":"information related to the cellular classification or pathology of a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues, as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3178317v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3178317","version":"1","preferredName":"Malignant Neoplasm Pathology Clinical Trial Eligibility Criteria","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004:A specialty concerned with the nature and cause of disease as expressed by changes in cellular or tissue structure and function caused by the disease process. (MSH98):Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C9305:C18189:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pathology","conceptCode":"C18189","definition":"The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98668D9A-EA65-4F10-E040-BB89AD43093A","latestVersionIndicator":"Yes","beginDate":"2010-12-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-27","modifiedBy":"ONEDATA","dateModified":"2010-12-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98668D9A-EA76-4F10-E040-BB89AD43093A","latestVersionIndicator":"Yes","beginDate":"2010-12-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-27","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6450618","version":"1","preferredName":"Malignant Neoplasm Pathology Type","preferredDefinition":"the type of cellular classification of a malignant neoplasm.","longName":"3178989v1.0","context":"NRG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"80","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Clear cell adenocarcinoma","valueDescription":"Clear Cell Adenocarcinoma","ValueMeaning":{"publicId":"4039074","version":"1","preferredName":"Clear Cell Adenocarcinoma","longName":"4039074","preferredDefinition":"A malignant neoplasm composed of glandular epithelial clear cells.  Various architectural patterns may be seen, including papillary, tubulocystic, and solid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clear Cell Adenocarcinoma","conceptCode":"C3766","definition":"A malignant neoplasm composed of glandular epithelial clear cells.  Various architectural patterns may be seen, including papillary, tubulocystic, and solid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEFFA5EA-68A2-E8CD-E040-BB89AD4345DA","latestVersionIndicator":"Yes","beginDate":"2014-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-01-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F453A0-D9D8-5031-E053-F662850A339E","beginDate":"2018-09-28","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Squamous Cervical Cancer","valueDescription":"Squamous Cervical Cancer","ValueMeaning":{"publicId":"5045751","version":"1","preferredName":"Squamous Cervical Cancer","longName":"5045751","preferredDefinition":"Squamous Cervical Cancer","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24AF3F83-D70B-0AF7-E050-BB89AD437EA7","latestVersionIndicator":"Yes","beginDate":"2015-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8C6B-5176-E053-F662850A9222","beginDate":"2015-11-16","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Transitional Cell Carcinoma","valueDescription":"Transitional Cell Carcinoma","ValueMeaning":{"publicId":"3182041","version":"1","preferredName":"Transitional Cell Carcinoma","longName":"3182041","preferredDefinition":"A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transitional Cell Carcinoma","conceptCode":"C2930","definition":"A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9946BED9-27F0-40A8-E040-BB89AD43775F","latestVersionIndicator":"Yes","beginDate":"2011-01-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8C75-5176-E053-F662850A9222","beginDate":"2011-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Unclassified Carcinoma","valueDescription":"Unclassified Carcinoma","ValueMeaning":{"publicId":"3120329","version":"1","preferredName":"Unclassified Carcinoma","longName":"3120329","preferredDefinition":"Not arranged or included in any specific grouping.: A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unclassified","conceptCode":"C64486","definition":"Not arranged or included in any specific grouping.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AEE1D01-2A88-F246-E040-BB89AD433010","latestVersionIndicator":"Yes","beginDate":"2010-07-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8C7F-5176-E053-F662850A9222","beginDate":"2011-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Undifferentiated Carcinoma","valueDescription":"Undifferentiated Carcinoma","ValueMeaning":{"publicId":"2838871","version":"1","preferredName":"Undifferentiated Carcinoma","longName":"2838871","preferredDefinition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated Carcinoma","conceptCode":"C3692","definition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A9E389-5897-FD59-E040-BB89AD432A90","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8C89-5176-E053-F662850A9222","beginDate":"2011-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Vaginal cancer","valueDescription":"Vaginal cancer","ValueMeaning":{"publicId":"2567392","version":"1","preferredName":"Vaginal cancer","longName":"2567392","preferredDefinition":"Vaginal cancer","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaginal Cancer","conceptCode":"C0042237","definition":"Definition not available.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D44D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-18","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-18","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8C93-5176-E053-F662850A9222","beginDate":"2015-11-16","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Verrucous carcinoma","valueDescription":"Verrucous Lesion","ValueMeaning":{"publicId":"3235572","version":"1","preferredName":"Verrucous Lesion","longName":"3235572","preferredDefinition":"A raised growth on the surface of the skin or other organ.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Verrucous Lesion","conceptCode":"C5028","definition":"A papillomavirus related epithelial overgrowth. It can be located anywhere on the body though when it involves the perineal region it is generally referred to as condyloma acuminatum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A366F43E-378A-9973-E040-BB89AD43108C","latestVersionIndicator":"Yes","beginDate":"2011-05-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8C9D-5176-E053-F662850A9222","beginDate":"2012-12-31","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Villoglandular adenocarcinoma","valueDescription":"VILLOGLANDULAR CARCINOMA","ValueMeaning":{"publicId":"2562494","version":"1","preferredName":"VILLOGLANDULAR CARCINOMA","longName":"2562494","preferredDefinition":"Villoglandular carcinoma ","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C12B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-01","endDate":null,"createdBy":"PWEST","dateCreated":"2002-10-01","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8CB1-5176-E053-F662850A9222","beginDate":"2011-06-08","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Mesonephric carcinoma","valueDescription":"Mesonephric carcinoma","ValueMeaning":{"publicId":"6450639","version":"1","preferredName":"Mesonephric carcinoma","longName":"6450639","preferredDefinition":"Arise from remnants of mesonephric (Wolffian) ducts, which form epididymis and vas deferens in males and persist in females as rete ovarii, paraoophoron and Gartner duct","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76F1ACE4-8A7C-5176-E053-F662850A9222","latestVersionIndicator":"Yes","beginDate":"2018-09-28","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8A95-5176-E053-F662850A9222","beginDate":"2018-09-28","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Adenocarcinoma","valueDescription":"Adenocarcinoma","ValueMeaning":{"publicId":"2831117","version":"1","preferredName":"Adenocarcinoma","longName":"2831117","preferredDefinition":"carcinoma derived from glandular tissue or in which tumor cells form recognizable glandular structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61F598EF-7D06-BDE9-E040-BB89AD43552F","latestVersionIndicator":"Yes","beginDate":"2009-02-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8A9F-5176-E053-F662850A9222","beginDate":"2011-01-24","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Adenocarcinoma NOS","valueDescription":"Adenocarcinoma NOS","ValueMeaning":{"publicId":"2573507","version":"1","preferredName":"Adenocarcinoma NOS","longName":"2573507","preferredDefinition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EC30-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"DWARZEL","dateModified":"2019-04-02","changeDescription":"Added concept code - adenocarcinoma NOS is shown as a synonym for this concept in NCIt DW 04-02-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8AA9-5176-E053-F662850A9222","beginDate":"2018-08-17","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Adenocarcinoma of the cervix","valueDescription":"Adenocarcinoma of the cervix","ValueMeaning":{"publicId":"5045753","version":"1","preferredName":"Adenocarcinoma of the cervix","longName":"5045753","preferredDefinition":"Adenocarcinoma of the cervix","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24AF3F83-D751-0AF7-E050-BB89AD437EA7","latestVersionIndicator":"Yes","beginDate":"2015-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8AB3-5176-E053-F662850A9222","beginDate":"2015-11-16","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Adenocarcinoma Unspecified","valueDescription":"Unspecified Adenocarcinoma","ValueMeaning":{"publicId":"3182038","version":"1","preferredName":"Unspecified Adenocarcinoma","longName":"3182038","preferredDefinition":"Not stated explicitly or in detail.: carcinoma derived from glandular tissue or in which tumor cells form recognizable glandular structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unspecified","conceptCode":"C38046","definition":"Not stated explicitly or in detail.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9946BED9-2736-40A8-E040-BB89AD43775F","latestVersionIndicator":"Yes","beginDate":"2011-01-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8ABD-5176-E053-F662850A9222","beginDate":"2012-08-29","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Adenocarcinoma with Squamous Differentiation","valueDescription":"Adenocarcinoma w/ Squamous Differentiation","ValueMeaning":{"publicId":"3232826","version":"1","preferredName":"Adenocarcinoma w/ Squamous Differentiation","longName":"3232826","preferredDefinition":"Adenocarcinoma w/ Squamous Differentiation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2605BA7-8CFA-4407-E040-BB89AD4335A4","latestVersionIndicator":"Yes","beginDate":"2011-05-03","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8AD1-5176-E053-F662850A9222","beginDate":"2011-05-03","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Adenocarcinoma in situ","valueDescription":"Adenocarcinoma, in situ","ValueMeaning":{"publicId":"3346879","version":"1","preferredName":"Adenocarcinoma, in situ","longName":"3346879","preferredDefinition":"A lesion in which the normally situated glands are partially or completely replaced by atypical cells with malignant characteristics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma In Situ","conceptCode":"C4123","definition":"A lesion in which the normally situated glands are partially or completely replaced by atypical cells with malignant characteristics.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B61EBCA6-FA8A-5FA8-E040-BB89AD436C77","latestVersionIndicator":"Yes","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"DWARZEL","dateModified":"2019-03-20","changeDescription":"Added concept code DW 03-20-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8AE5-5176-E053-F662850A9222","beginDate":"2012-12-31","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Adenoid Cystic Carcinoma","valueDescription":"Adenoid Cystic Carcinoma","ValueMeaning":{"publicId":"2836817","version":"1","preferredName":"Adenoid Cystic Carcinoma","longName":"2836817","preferredDefinition":"A malignant tumor arising from the epithelial cells, also known as cylindroma.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoid Cystic Carcinoma","conceptCode":"C2970","definition":"A malignant tumor arising from the epithelial cells.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"624748BE-AA6A-D571-E040-BB89AD4336CB","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8AEF-5176-E053-F662850A9222","beginDate":"2011-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Adenosarcoma","valueDescription":"Adenosarcoma","ValueMeaning":{"publicId":"3247916","version":"1","preferredName":"Adenosarcoma","longName":"3247916","preferredDefinition":"A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenosarcoma","conceptCode":"C9474","definition":"A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A67B3AED-056E-CE90-E040-BB89AD433EDB","latestVersionIndicator":"Yes","beginDate":"2011-06-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-24","modifiedBy":"COOPERM","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8AF9-5176-E053-F662850A9222","beginDate":"2012-12-31","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Adenosquamous","valueDescription":"Adenosquamous Carcinoma","ValueMeaning":{"publicId":"2836818","version":"1","preferredName":"Adenosquamous Carcinoma","longName":"2836818","preferredDefinition":"A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenosquamous Carcinoma","conceptCode":"C3727","definition":"An invasive carcinoma composed of malignant glandular cells and malignant squamous cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-0687-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8B03-5176-E053-F662850A9222","beginDate":"2011-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Carcinosarcoma heterologous","valueDescription":"Carcinosarcoma - heterologous","ValueMeaning":{"publicId":"3178990","version":"1","preferredName":"Carcinosarcoma - heterologous","longName":"3178990","preferredDefinition":"A carcinosarcoma of the uterus characterized by the presence of sarcomatous elements composed of tissues that are not found in the uterus (e.g., bone, cartilage, skeletal muscle).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Carcinosarcoma, Heterologous Type","conceptCode":"C113239","definition":"A carcinosarcoma of the uterus characterized by the presence of sarcomatous elements composed of tissues that are not found in the uterus (e.g., bone, cartilage, skeletal muscle).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"986B514C-4A65-E2CB-E040-BB89AD433A07","latestVersionIndicator":"Yes","beginDate":"2010-12-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-27","modifiedBy":"DWARZEL","dateModified":"2019-03-20","changeDescription":"Added concept code DW 03-20-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8B17-5176-E053-F662850A9222","beginDate":"2010-12-27","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Carcinosarcoma homologous","valueDescription":"Carcinosarcoma - homologous","ValueMeaning":{"publicId":"3178991","version":"1","preferredName":"Carcinosarcoma - homologous","longName":"3178991","preferredDefinition":"A carcinosarcoma of the uterus characterized by the presence of sarcomatous elements that arise from the tissues of the uterus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Carcinosarcoma, Homologous Type","conceptCode":"C113238","definition":"A carcinosarcoma of the uterus characterized by the presence of sarcomatous elements that arise from the tissues of the uterus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"986B514C-4A88-E2CB-E040-BB89AD433A07","latestVersionIndicator":"Yes","beginDate":"2010-12-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-27","modifiedBy":"DWARZEL","dateModified":"2019-06-20","changeDescription":"Added concept DW -6-20-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8B2B-5176-E053-F662850A9222","beginDate":"2010-12-27","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Carcinosarcoma type unspecified","valueDescription":"Carcinosarcoma, type unspecified","ValueMeaning":{"publicId":"3185164","version":"1","preferredName":"Carcinosarcoma, type unspecified","longName":"3185164","preferredDefinition":"A malignant tumor composed of a mixture of carcinomatous and sarcomatous elements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinosarcoma","conceptCode":"C34448","definition":"A malignant tumor composed of a mixture of carcinomatous and sarcomatous elements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A5034CF-29F9-DD89-E040-BB89AD436D64","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"DWARZEL","dateModified":"2019-06-20","changeDescription":"Add concept code  per EVS recommendation of which concept to use - DW 06202019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8B3F-5176-E053-F662850A9222","beginDate":"2011-01-20","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Cervical cancer NOS","valueDescription":"Cervical cancer, NOS","ValueMeaning":{"publicId":"5045752","version":"1","preferredName":"Cervical cancer, NOS","longName":"5045752","preferredDefinition":"Cervical cancer, NOS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24AF3F83-D72E-0AF7-E050-BB89AD437EA7","latestVersionIndicator":"Yes","beginDate":"2015-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8B53-5176-E053-F662850A9222","beginDate":"2015-11-16","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Clear cell","valueDescription":"Clear Cell","ValueMeaning":{"publicId":"2575069","version":"1","preferredName":"Clear Cell","longName":"2575069","preferredDefinition":"Clear Cell","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F24A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-05-24","modifiedBy":"REEVESD","dateModified":"2005-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8B5D-5176-E053-F662850A9222","beginDate":"2017-03-15","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Clear cell carcinoma","valueDescription":"Clear cell carcinoma","ValueMeaning":{"publicId":"3183597","version":"1","preferredName":"Clear cell carcinoma","longName":"3183597","preferredDefinition":"A malignant neoplasm composed of glandular epithelial clear cells.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A0CF32C-262D-DEE4-E040-BB89AD432D65","latestVersionIndicator":"Yes","beginDate":"2011-01-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-01-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8B67-5176-E053-F662850A9222","beginDate":"2011-01-17","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Endodermal sinus tumor","valueDescription":"ENDODERMAL SINUS TUMOR (YOLK SAC TUMOR)","ValueMeaning":{"publicId":"2558716","version":"1","preferredName":"ENDODERMAL SINUS TUMOR (YOLK SAC TUMOR)","longName":"2558716","preferredDefinition":"ENDODERMAL SINUS TUMOR (YOLK SAC TUMOR)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B269-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8B71-5176-E053-F662850A9222","beginDate":"2012-12-31","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Endometrioid Adenocarcinoma","valueDescription":"Endometrioid Adenocarcinoma","ValueMeaning":{"publicId":"3183464","version":"1","preferredName":"Endometrioid Adenocarcinoma","longName":"3183464","preferredDefinition":"An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian carcinoma and endometrial carcinoma. There is a high frequency of cooccurence of this form of adenocarcinoma in both tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrioid Adenocarcinoma","conceptCode":"C3769","definition":"An adenocarcinoma characterized by the presence of malignant glandular epithelial cells resembling endometrial cells. It can arise from the uterine body, ovary, fallopian tube, cervix, vagina, and uterine ligament.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D549A4-47A4-E906-E040-BB89AD430D41","latestVersionIndicator":"Yes","beginDate":"2011-01-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-01-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8B7B-5176-E053-F662850A9222","beginDate":"2011-01-14","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Endometrioid grade 3","valueDescription":"Endometrioid grade 3","ValueMeaning":{"publicId":"5711162","version":"1","preferredName":"Endometrioid grade 3","longName":"5711162","preferredDefinition":"Endometrioid grade 3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AC83789-74F1-0775-E053-F662850AA322","latestVersionIndicator":"Yes","beginDate":"2017-03-15","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8B85-5176-E053-F662850A9222","beginDate":"2017-03-15","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Epithelial carcinoma","valueDescription":"Epithelial carcinoma","ValueMeaning":{"publicId":"6331572","version":"1","preferredName":"Epithelial carcinoma","longName":"6331572","preferredDefinition":"Epithelial carcinoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6DFAE86F-13B6-5731-E053-F662850A05A0","latestVersionIndicator":"Yes","beginDate":"2018-06-06","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-06-06","modifiedBy":"ONEDATA","dateModified":"2018-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8B8F-5176-E053-F662850A9222","beginDate":"2018-06-06","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Follicular Lymphoma","valueDescription":"Follicular Lymphoma","ValueMeaning":{"publicId":"3088584","version":"1","preferredName":"Follicular Lymphoma","longName":"3088584","preferredDefinition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Lymphoma","conceptCode":"C3209","definition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E3DD57-D19B-A26A-E040-BB89AD437117","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8B99-5176-E053-F662850A9222","beginDate":"2011-05-19","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Glass Cell Carcinoma","valueDescription":"Glass Cell Carcinoma","ValueMeaning":{"publicId":"3182040","version":"1","preferredName":"Glass Cell Carcinoma","longName":"3182040","preferredDefinition":"a poorly differentiated variant of adenosquamous carcinoma of the cervix associated with an aggressive course and a poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9946BED9-2790-40A8-E040-BB89AD43775F","latestVersionIndicator":"Yes","beginDate":"2011-01-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8BA3-5176-E053-F662850A9222","beginDate":"2011-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"High grade serous","valueDescription":"High grade serous","ValueMeaning":{"publicId":"5711163","version":"1","preferredName":"High grade serous","longName":"5711163","preferredDefinition":"High grade serous","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AC83789-751E-0775-E053-F662850AA322","latestVersionIndicator":"Yes","beginDate":"2017-03-15","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8BAD-5176-E053-F662850A9222","beginDate":"2017-03-15","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Large Cell Carcinoma","valueDescription":"Large Cell Carcinoma","ValueMeaning":{"publicId":"2956073","version":"1","preferredName":"Large Cell Carcinoma","longName":"2956073","preferredDefinition":"These represent the least common histologic subtype of lung cancers comprising approximately 15% of all lung cancers.  The frequency is decreasing with improved classification through refined histopathological analysis of these tumors as poorly differentiated squamous cell carcinomas or adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Large Cell Carcinoma","conceptCode":"C3780","definition":"A malignant epithelial neoplasm composed of large, atypical cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76EBECE2-B751-A0E2-E040-BB89AD435984","latestVersionIndicator":"Yes","beginDate":"2009-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-10-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8BB7-5176-E053-F662850A9222","beginDate":"2011-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Leiomyosarcoma","valueDescription":"Leiomyosarcoma","ValueMeaning":{"publicId":"2562491","version":"1","preferredName":"Leiomyosarcoma","longName":"2562491","preferredDefinition":"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women. It is characterized by a proliferation of neoplastic spindle cells. Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leiomyosarcoma","conceptCode":"C3158","definition":"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women.  It is characterized by a proliferation of neoplastic spindle cells.  Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C128-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-09-27","endDate":null,"createdBy":"PWEST","dateCreated":"2002-09-27","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8BC1-5176-E053-F662850A9222","beginDate":"2012-12-31","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Malignant Brenners Tumor","valueDescription":"Malignant Ovarian Brenner Tumor","ValueMeaning":{"publicId":"3120341","version":"1","preferredName":"Malignant Ovarian Brenner Tumor","longName":"3120341","preferredDefinition":"A Brenner tumor of the ovary characterized by a cytologically malignant cell population and stromal invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Ovarian Brenner Tumor","conceptCode":"C4270","definition":"A malignant neoplasm that arises from the ovary. It is characterized by the presence of an invasive malignant urothelial-type cellular component and nests of benign urothelial-type cells in a fibrotic stroma. When the neoplasm is confined to the ovary, the prognosis is good.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AEE1D01-2AD5-F246-E040-BB89AD433010","latestVersionIndicator":"Yes","beginDate":"2010-07-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8BCB-5176-E053-F662850A9222","beginDate":"2011-02-10","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Mixed Epithelial Carcinoma","valueDescription":"Mixed Epithelial Carcinoma","ValueMeaning":{"publicId":"3182039","version":"1","preferredName":"Mixed Epithelial Carcinoma","longName":"3182039","preferredDefinition":"A malignant mixed epithelial neoplasm that arises from the ovary and is composed predominantly of serous and endocervical-type mucinous epithelium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Seromucinous Carcinoma","conceptCode":"C40090","definition":"A malignant mixed epithelial neoplasm that arises from the ovary and is composed predominantly of serous and endocervical-type mucinous cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9946BED9-276D-40A8-E040-BB89AD43775F","latestVersionIndicator":"Yes","beginDate":"2011-01-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-01-07","modifiedBy":"DWARZEL","dateModified":"2019-03-20","changeDescription":"Added concept code DW 03-20-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8BD5-5176-E053-F662850A9222","beginDate":"2011-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Mucinous Adenocarcinoma","valueDescription":"Mucinous Adenocarcinoma","ValueMeaning":{"publicId":"2838623","version":"1","preferredName":"Mucinous Adenocarcinoma","longName":"2838623","preferredDefinition":"An invasive adenocarcinoma composed of malignant glandular cells which contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucinous Adenocarcinoma","conceptCode":"C26712","definition":"An invasive adenocarcinoma composed of malignant glandular cells which contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-596B-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"HARTLEYG","dateModified":"2017-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8BDF-5176-E053-F662850A9222","beginDate":"2011-01-14","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Non-Squamous Cell Carcinoma","valueDescription":"Non-squamous cell carcinoma","ValueMeaning":{"publicId":"2932105","version":"1","preferredName":"Non-squamous cell carcinoma","longName":"2932105","preferredDefinition":"A poorly differentiated non-small cell lung carcinoma composed of large polygonal cells without evidence of glandular or squamous differentiation.  There is a male predilection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Large Cell Carcinoma","conceptCode":"C4450","definition":"An undifferentiated non-small cell lung carcinoma composed of large polygonal cells without evidence of glandular, squamous, or neuroendocrine differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"70DF89DB-8A04-2C9A-E040-BB89AD4367D1","latestVersionIndicator":"Yes","beginDate":"2009-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-08-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8BE9-5176-E053-F662850A9222","beginDate":"2012-01-10","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Other Carcinoma","valueDescription":"Other Carcinoma","ValueMeaning":{"publicId":"3120330","version":"1","preferredName":"Other Carcinoma","longName":"3120330","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AEE1D01-2AAE-F246-E040-BB89AD433010","latestVersionIndicator":"Yes","beginDate":"2010-07-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8BF3-5176-E053-F662850A9222","beginDate":"2013-01-16","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Sarcoma other type","valueDescription":"Sarcoma, other type","ValueMeaning":{"publicId":"3647888","version":"1","preferredName":"Sarcoma, other type","longName":"3647888","preferredDefinition":"Sarcoma, other type","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D22CCE35-6F52-DA46-E040-BB89AD430CA0","latestVersionIndicator":"Yes","beginDate":"2012-12-31","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-12-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8C07-5176-E053-F662850A9222","beginDate":"2012-12-31","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Sarcoma unspecified","valueDescription":"Sarcoma NOS","ValueMeaning":{"publicId":"3155794","version":"1","preferredName":"Sarcoma NOS","longName":"3155794","preferredDefinition":"A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoma","conceptCode":"C9118","definition":"A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"942FF03C-0577-584B-E040-BB89AD4324F7","latestVersionIndicator":"Yes","beginDate":"2010-11-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-11-03","modifiedBy":"DWARZEL","dateModified":"2019-03-21","changeDescription":"Added concept DW 03-21-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8C1B-5176-E053-F662850A9222","beginDate":"2012-12-31","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Serous adenocarcinoma","valueDescription":"Serous Adenocarcinoma","ValueMeaning":{"publicId":"3183465","version":"1","preferredName":"Serous Adenocarcinoma","longName":"3183465","preferredDefinition":"Definition not available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Serous Adenocarcinoma","conceptCode":"C40101","definition":"An adenocarcinoma that is characterized by the presence of papillary patterns and cellular budding. Psammoma bodies may be present.  Representative examples include cervical serous adenocarcinoma, endometrial serous adenocarcinoma, ovarian serous adenocarcinoma, and primary peritoneal serous adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D549A4-47D1-E906-E040-BB89AD430D41","latestVersionIndicator":"Yes","beginDate":"2011-01-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-01-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8C25-5176-E053-F662850A9222","beginDate":"2011-01-14","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Small Cell Carcinoma","valueDescription":"Pancreatic Small Cell Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"2838839","version":"1","preferredName":"Pancreatic Small Cell Neuroendocrine Carcinoma","longName":"2838839","preferredDefinition":"An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas.  It is characterized by the presence of malignant small cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Small Cell Neuroendocrine Carcinoma","conceptCode":"C95583","definition":"An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas. It is characterized by the presence of malignant small cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A9743A-23D9-8C94-E040-BB89AD4308C2","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"HARTLEYG","dateModified":"2017-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8C2F-5176-E053-F662850A9222","beginDate":"2011-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Squamous Cell Carcinoma","valueDescription":"Squamous Cell Carcinoma","ValueMeaning":{"publicId":"2567412","version":"1","preferredName":"Squamous Cell Carcinoma","longName":"2567412","preferredDefinition":"A carcinoma derived from stratified squamous epithelium. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Squamous Cell Carcinoma","conceptCode":"C2929","definition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D461-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8C39-5176-E053-F662850A9222","beginDate":"2011-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Squamous cell carcinoma in situ","valueDescription":"Squamous Cell Carcinoma, in situ","ValueMeaning":{"publicId":"3346877","version":"1","preferredName":"Squamous Cell Carcinoma, in situ","longName":"3346877","preferredDefinition":"Squamous Cell Carcinoma, in situ","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B61EBCA6-F8BD-5FA8-E040-BB89AD436C77","latestVersionIndicator":"Yes","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8C4D-5176-E053-F662850A9222","beginDate":"2012-12-31","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Squamous cell carcinoma invasive","valueDescription":"Squamous cell carcinoma, invasive","ValueMeaning":{"publicId":"3243061","version":"1","preferredName":"Squamous cell carcinoma, invasive","longName":"3243061","preferredDefinition":"Squamous cell carcinoma, invasive","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A537147F-3935-B22A-E040-BB89AD430A3F","latestVersionIndicator":"Yes","beginDate":"2011-06-08","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76F1ACE4-8C61-5176-E053-F662850A9222","beginDate":"2011-06-08","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"ONEDATA","dateModified":"2018-09-28","deletedIndicator":"No"},{"value":"Dedifferentiated/Undifferentiated carcinoma","valueDescription":"Dedifferentiated/Undifferentiated carcinoma","ValueMeaning":{"publicId":"6810187","version":"1","preferredName":"Dedifferentiated/Undifferentiated carcinoma","longName":"6810187","preferredDefinition":"Dedifferentiated/Undifferentiated carcinoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C9FD909-1071-302A-E053-F662850A13AC","latestVersionIndicator":"Yes","beginDate":"2019-07-01","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-07-01","modifiedBy":"ONEDATA","dateModified":"2019-07-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C9FD909-108A-302A-E053-F662850A13AC","beginDate":"2019-07-01","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-07-01","modifiedBy":"ONEDATA","dateModified":"2019-07-01","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"6431768","version":"1","preferredName":"Other","longName":"6431768v1.00","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"762A692A-EEF7-29A1-E053-F662850A9EA9","latestVersionIndicator":"Yes","beginDate":"2018-09-18","endDate":null,"createdBy":"WINCHC","dateCreated":"2018-09-18","modifiedBy":"GDEEN","dateModified":"2024-01-22","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91F49C2F-6CE5-644A-E053-F662850A2672","beginDate":"2019-09-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-09-07","modifiedBy":"ONEDATA","dateModified":"2019-09-07","deletedIndicator":"No"},{"value":"Mixed epithelial","valueDescription":"Mixed epithelial","ValueMeaning":{"publicId":"4908978","version":"1","preferredName":"Mixed epithelial","longName":"4908978","preferredDefinition":"Mixed epithelial","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7A84-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSANE","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F11A2B6-14CA-2981-E053-F662850AC34F","beginDate":"2019-08-01","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-08-01","modifiedBy":"ONEDATA","dateModified":"2019-08-01","deletedIndicator":"No"},{"value":"High grade endometrioid","valueDescription":"High grade endometrioid","ValueMeaning":{"publicId":"6841851","version":"1","preferredName":"High grade endometrioid","longName":"6841851","preferredDefinition":"High grade endometrioid","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F11A2B6-14D4-2981-E053-F662850AC34F","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-08-01","modifiedBy":"ONEDATA","dateModified":"2019-08-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F11A2B6-14ED-2981-E053-F662850AC34F","beginDate":"2019-08-01","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-08-01","modifiedBy":"ONEDATA","dateModified":"2019-08-01","deletedIndicator":"No"},{"value":"Carcinoma, NOS","valueDescription":"Carcinoma","ValueMeaning":{"publicId":"2935533","version":"1","preferredName":"Carcinoma","longName":"2935533","preferredDefinition":"A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71F88553-C4BB-17CC-E040-BB89AD43398B","latestVersionIndicator":"Yes","beginDate":"2009-08-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-08-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B929269-E72C-55AE-E053-F662850ABB8E","beginDate":"2020-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","deletedIndicator":"No"},{"value":"Carcinosarcoma","valueDescription":"Carcinosarcoma","ValueMeaning":{"publicId":"3248559","version":"1","preferredName":"Carcinosarcoma","longName":"3248559","preferredDefinition":"A malignant tumor composed of a mixture of carcinomatous and sarcomatous elements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinosarcoma","conceptCode":"C34448","definition":"A malignant tumor composed of a mixture of carcinomatous and sarcomatous elements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BBE041-BD1E-9503-E040-BB89AD435A00","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B929269-E740-55AE-E053-F662850ABB8E","beginDate":"2020-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","deletedIndicator":"No"},{"value":"Serous","valueDescription":"Serous","ValueMeaning":{"publicId":"3300681","version":"1","preferredName":"Serous","longName":"3300681","preferredDefinition":"Of or producing or containing serum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Serous","conceptCode":"C14168","definition":"Of or producing or containing serum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B126E752-C570-5EF2-E040-BB89AD43398A","latestVersionIndicator":"Yes","beginDate":"2011-11-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-11-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B929269-E736-55AE-E053-F662850ABB8E","beginDate":"2020-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","deletedIndicator":"No"},{"value":"Endometrioid grade 2","valueDescription":"Endometrioid grade 2","ValueMeaning":{"publicId":"7124505","version":"1","preferredName":"Endometrioid grade 2","longName":"7124505","preferredDefinition":"Endometrioid grade 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B929269-E74A-55AE-E053-F662850ABB8E","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B929269-E763-55AE-E053-F662850ABB8E","beginDate":"2020-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","deletedIndicator":"No"},{"value":"Endometrioid grade 1","valueDescription":"Endometrioid grade 1","ValueMeaning":{"publicId":"7124506","version":"1","preferredName":"Endometrioid grade 1","longName":"7124506","preferredDefinition":"Endometrioid grade 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B929269-E76D-55AE-E053-F662850ABB8E","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B929269-E786-55AE-E053-F662850ABB8E","beginDate":"2020-01-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","deletedIndicator":"No"},{"value":"Mucinous","valueDescription":"Mucinous","ValueMeaning":{"publicId":"2575132","version":"1","preferredName":"Mucinous","longName":"2575132","preferredDefinition":"Mucinous","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F289-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-05-24","modifiedBy":"REEVESD","dateModified":"2005-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56A1CE1-3506-4C4E-E053-4EBD850A8DA7","beginDate":"2020-12-01","endDate":null,"createdBy":"SARAHB","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Low grade serous","valueDescription":"Low grade serous","ValueMeaning":{"publicId":"7518898","version":"1","preferredName":"Low grade serous","longName":"7518898","preferredDefinition":"Low grade serous","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56A1CE1-3510-4C4E-E053-4EBD850A8DA7","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"SARAHB","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B56A1CE1-3529-4C4E-E053-4EBD850A8DA7","beginDate":"2020-12-01","endDate":null,"createdBy":"SARAHB","dateCreated":"2020-12-01","modifiedBy":"ONEDATA","dateModified":"2020-12-01","deletedIndicator":"No"},{"value":"Dedifferentiated/undifferentiated","valueDescription":"Dedifferentiated/undifferentiated","ValueMeaning":{"publicId":"7752356","version":"1","preferredName":"Dedifferentiated/undifferentiated","longName":"7752356","preferredDefinition":"Dedifferentiated/undifferentiated","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C8455010-7ED8-1321-E053-4EBD850A3134","latestVersionIndicator":"Yes","beginDate":"2021-07-29","endDate":null,"createdBy":"BOWSERC","dateCreated":"2021-07-29","modifiedBy":"ONEDATA","dateModified":"2021-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C8455010-7EF1-1321-E053-4EBD850A3134","beginDate":"2021-07-29","endDate":null,"createdBy":"BOWSERC","dateCreated":"2021-07-29","modifiedBy":"ONEDATA","dateModified":"2021-07-29","deletedIndicator":"No"},{"value":"Equivocal with aberrant p53","valueDescription":"Equivocal with aberrant p53","ValueMeaning":{"publicId":"7843081","version":"1","preferredName":"Equivocal with aberrant p53","longName":"7843081","preferredDefinition":"Equivocal with aberrant p53","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D177ABE4-D651-4AAE-E053-4EBD850ABBCA","latestVersionIndicator":"Yes","beginDate":"2021-11-23","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2021-11-23","modifiedBy":"ONEDATA","dateModified":"2021-11-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D177ABE4-D66A-4AAE-E053-4EBD850ABBCA","beginDate":"2021-11-23","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2021-11-23","modifiedBy":"ONEDATA","dateModified":"2021-11-23","deletedIndicator":"No"},{"value":"Malignant Brenner Tumor","valueDescription":"Malignant Brenner Tumor","ValueMeaning":{"publicId":"3704508","version":"1","preferredName":"Malignant Brenner Tumor","longName":"3704508","preferredDefinition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.: A usually benign tumor composed of solid and cystic nests of epithelial cells resembling transitional epithelium; it is surrounded by an abundant stromal component that is dense and fibroblastic in nature.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant","conceptCode":"C14143","definition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Brenner Tumor","conceptCode":"C39954","definition":"A tumor composed of solid and cystic nests of neoplastic urothelial-type cells in an abundant stromal component that is dense and fibroblastic in nature. It arises from the ovary and very rarely the paratesticular structures. It includes benign Brenner tumor, borderline Brenner tumor, and malignant Brenner tumor.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D8FCE429-D3D2-B178-E040-BB89AD430EA5","latestVersionIndicator":"Yes","beginDate":"2013-03-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DBD5AB8A-993E-7D14-E053-4EBD850A5515","beginDate":"2022-04-04","endDate":null,"createdBy":"SARAHB","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76F1ACE4-8965-5176-E053-F662850A9222","latestVersionIndicator":"Yes","beginDate":"2018-09-28","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"SARAHB","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What is the histologic cell t","type":"Preferred Question Text","description":"What is the histologic cell type?","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76F1BBFD-4BC7-0AF0-E053-F662850A73C3","latestVersionIndicator":"Yes","beginDate":"2018-09-28","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"VUJANOVA","dateModified":"2019-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}